# EDGAR Filing Document

**Accession Number:** 0001006281
**File Stem:** 0001104659-25-080754
**Filing Date:** 2025-8
**Character Count:** 2566
**Document Hash:** 6f2ebe5f64e508d1362181eae5271434
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-080754.hdr.sgml**: 20250922

**ACCESSION NUMBER**: 0001104659-25-080754

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250820

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Protalix BioTherapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001006281
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 650643773
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 2 UNIVERSITY PLAZA
- **STREET 2:** SUITE 100
- **CITY:** HACKENSACK
- **STATE:** NJ
- **ZIP:** 07601
- **BUSINESS PHONE:** 201-696-9345

**MAIL ADDRESS:**
- **STREET 1:** 2 UNIVERSITY PLAZA
- **STREET 2:** SUITE 100
- **CITY:** HACKENSACK
- **STATE:** NJ
- **ZIP:** 07601

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ORTHODONTIX INC
- **DATE OF NAME CHANGE:** 19980422

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** EMBASSY ACQUISITION CORP
- **DATE OF NAME CHANGE:** 19960124

![Protalix BioTherapeutics Announces Presentations at the 17th ...](image_001.jpg)

August 20, 2025

<u>Via EDGAR</u>

 ****

Securities and Exchange Commission

Division of Corporation Finance

Office of Finance

100 F Street, N.E.

Washington, D.C. 20549

---

| | |
|:---|:---|
| Re: | **Protalix BioTherapeutics, Inc.** |
|  | **Registration Statement on Form S-3** |
|  | **File No. 333-286802** |

---

To whom it may concern:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Protalix BioTherapeutics, Inc. (the "<u>Company</u>") hereby respectfully requests that the effective date of the above-referenced Registration Statement on Form S-3 be accelerated by the Securities and Exchange Commission to 4:00 p.m. Eastern Time on August 22, 2025, or as soon as practicable thereafter.

The Company requests that we be notified of such effectiveness by a telephone call to Brian Hirshberg of Mayer Brown LLP at +1 (212) 506-2176.

---

| | | |
|:---|:---|:---|
| Very truly yours, | Very truly yours, | Very truly yours, |
| **Protalix BioTherapeutics, Inc.** | **Protalix BioTherapeutics, Inc.** | **Protalix BioTherapeutics, Inc.** |
| By: | /s/ Eyal Rubin | /s/ Eyal Rubin |
|  | Name: | Eyal Rubin |
|  | Title: | Sr. Vice President and Chief Financial Officer |

---

---

| | |
|:---|:---|
| cc: | Dror Bashan |
|  | Protalix BioTherapeutics, Inc. |
|  | Brian Hirshberg |
|  | Mayer Brown LLP |

---